試す 金 - 無料
“We are investing in larger cleanrooms, better QA vision systems, and more technical expertise”
BioSpectrum Asia
|October 2020
Oliver Healthcare Packaging, one of the leading providers of sterile barrier flexible packaging for the global healthcare industry, emphasize on custom engineered design of Sterile Barrier System (SBS) to meet medical innovations and packaging technologies. Oliver Healthcare with its state-of-the-art manufacturing facility, expanding global SBS manufacturing footprint to Asian market. Mike Benevento, President & CEO, Oliver Healthcare Packaging, Princeton, New Jersey, USA, further elaborates on the critical role of SBS and its significance as integral part of Asia Pacific (APAC) MedTech industry. Edited excerpts;

How do you assess the primacies in the development of sterile barrier systems (SBS)?
The aseptic operations at medical devices and pharmaceuticals industry comprises of unique challenges, opportunities, and most importantly the regulatory landscape. Those developing devices and drugs should engage packaging firms with dedicated design and technical expertise to design and develop medical sterile barrier systems. Organizations often undertake some form of in-house development of their SBS. This can be driven by many factors, including cost savings, and can be valuable in setting the stage. Yet, as part of regulatory due diligence, it is essential to note that there are complex SBS vulnerabilities that may be unknown to the product design team. Engaging with a medical packaging team can take early concepts to optimal solutions and success.
How do you foresee APAC healthcare SBS market?
The market in Asia Pacific (APAC) is well-positioned to serve its growing MedTech industry. An aging population, higher access to healthcare services, and growing disposable incomes fuel the APAC region’s market potential and opportunities. Today, a large portion of the market produces lower-end class I and II devices, but we also see growth in higher-end (class II and III) device manufacturing, which are typically more challenging from a packaging standpoint.
このストーリーは、BioSpectrum Asia の October 2020 版からのものです。
Magzter GOLD を購読すると、厳選された何千ものプレミアム記事や、9,500 以上の雑誌や新聞にアクセスできます。
すでに購読者ですか? サインイン
BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia
Collaborative R&D: Partnerships shaping the future of biopharma
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
2 mins
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Quantum Computing: Future of diagnostics is being coded today
A silent revolution is being built at the intersection of biology and quantum physics. After decades of pushing the boundaries of diagnostics with advanced imaging and AI, we are now approaching a hard computational wall. For complex conditions like Alzheimer's, Parkinson's, and many cancers, the interacting variables of genomics, proteomics, and real-world patient data are simply too vast for classical computers to master. This limitation caps the ability to move from merely spotting correlations to uncovering true causation. Unlike traditional AI, quantum computing can simulate underlying physical systems to derive precise solutions. The transition from correlational analysis to causal simulation will enable a more valuable and advanced frontier in diagnostics.
4 mins
BioSpectrum Asia Sep 2025
BioSpectrum Asia
First Pacific woman to serve as public health director in NZ
The Ministry of Health in New Zealand (NZ) has appointed Dr Corina Grey as the new Director of Public Health this year, a landmark appointment for Pacific leadership.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Bio-Rad appoints Rajat Mehta as Executive Vice President of Global Commercial Operations
Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, has announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective August 4, 2025.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Hugel launches botulinum toxin Letybo in Malaysia
South Korea-based Hugel Inc., a leading global medical aesthetics company, has officially launched its botulinum toxin product Letybo in Malaysia - an emerging market for medical aesthetics in Southeast Asia.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Australia designs smart wound monitor to improve chronic infection care
Researchers from Australia's RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Revvity unveils innovative reagent technology to accelerate therapeutics development
US-based Revvity, Inc. has announced the launch of pHSense reagents, a powerful technology designed to advance internalisation studies in drug discovery.
1 min
BioSpectrum Asia Sep 2025

BioSpectrum Asia
Sanofi acquires next-gen vaccine biotech Vicebio for $1.6 B
Vicebio, a biopharmaceutical company with operations in Australia, UK and Belgium, has entered an exclusive, definitive agreement to be acquired by Sanofi.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
HOSMAC signs MoU with Gulf Medical University to strengthen healthcare education
HOSMAC, Asia's leading hospital planning, design, and management consultancy, has signed a Memorandum of Understanding (MoU) with Gulf Medical University (GMU), Ajman, UAE, to serve as an industry partner.
1 min
BioSpectrum Asia Sep 2025
BioSpectrum Asia
Jessica Cowden takes charge as Deputy Director General of CARE unit at IVI
Dr Jessica Cowden has been appointed Deputy Director General of the Clinical, Assessment, Regulatory, Evaluation (CARE) unit at South Korea-headquartered International Vaccine Institute (IVI). She will continue to be based at IVI's Europe Regional Office in Stockholm, Sweden.
1 min
BioSpectrum Asia Sep 2025
Translate
Change font size